Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial

Abstract

Our results provide further evidence that tamoxifen reduces the risk of myocardial infarction. Thromboembolic events should be carefully monitored in trials of tamoxifen, particularly those of prophylactic treatment, in which tamoxifen is given to healthy women.